Equities

Prophase Labs Inc

PRPH:NAQ

Prophase Labs Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.7445
  • Today's Change-0.024 / -3.17%
  • Shares traded113.27k
  • 1 Year change-83.42%
  • Beta-0.2732
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Oct-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for ProPhase Labs Inc have a median target of 18.50, with a high estimate of 21.00 and a low estimate of 16.00. The median estimate represents a 2,384.89% increase from the last price of 0.7445.
High2,720.7%21.00
Med2,384.9%18.50
Low2,049.1%16.00

Earnings history & estimates in USD

On Nov 13, 2024, ProPhase Labs Inc reported 3rd quarter 2024 losses of -0.35 per share.
The next earnings announcement is expected on Mar 13, 2025.
Average growth rate-90.30%
ProPhase Labs Inc reported annual 2023 losses of -0.98 per share on Mar 15, 2024.
Average growth rate+32.74%
More ▼

Revenue history & estimates in USD

ProPhase Labs, Inc. had 3rd quarter 2024 revenues of 3.15m. This missed the 23.85m estimate of the one analyst following the company. This was 83.70% below the prior year's 3rd quarter results.
Average growth rate-17.31%
ProPhase Labs, Inc. had revenues for the full year 2023 of 45.24m. This was 63.12% below the prior year's results.
Average growth rate+102.47%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.